Abstract
A specific and accurate blood test for acute brain injury could help monitor infarct growth in ischemic stroke and serve as a surrogate end point in clinical trials. Using a single-molecule detection assay, we assessed plasma brain-derived tau (BD-tau), a marker selectively quantifying tau protein from the central nervous system, in a prospective cohort of 502 patients with acute ischemic stroke with serial blood sampling from admission to day 7. Higher BD-tau concentrations at admission were associated with more extensive early brain injury on computed tomography and predicted larger final infarct volumes. BD-tau increases from admission to day 2 were related to infarct growth. BD-tau concentrations rose until day 7 and were higher in patients with secondary events, including recurrent stroke. After thrombectomy, the rise of BD-tau was smaller in patients with complete versus incomplete recanalization. BD-tau outperformed other blood markers and imaging metrics in predicting 90-day functional outcome across infarct size strata and time points. In an independent multicenter prospective cohort (N = 519), BD-tau showed higher performance than magnetic resonance imaging–derived final infarct volume in predicting functional outcomes at 3, 12, and 36 months. In the biomarker substudy of a phase 3 trial assessing nerinetide in patients with ischemic stroke (N = 193), BD-tau showed predictive performance comparable to the other cohorts, mediated the relationship between recanalization and functional outcome, and showed a 49% smaller increase in the nerinetide group versus placebo. Overall, plasma BD-tau tracked ischemic brain injury over time, outperformed other biomarkers in predicting functional outcomes, and identified possible treatment responses.
| Original language | English |
|---|---|
| Article number | eadz1280 |
| Journal | Science Translational Medicine |
| Volume | 18 |
| Issue number | 832 |
| Pages (from-to) | eadz1280 |
| ISSN | 1946-6234 |
| DOIs | |
| Publication status | Published - 14.01.2026 |
Funding
| Funders | Funder number |
|---|---|
| Medtronic | |
| University of Calgary | |
| Munich Cluster for Systems Neurology | 390857198 |
| Fondation Leducq | 21cVd04 |
| Corona-Stiftung | PJT-180434, S199/10081/2020 |
| Bundesministerium für Forschung, Technologie und Raumfahrt | lMUexcellent nFF-1507 |
| Friedrich‐Baur‐Stiftung | 2 en343/16-1 |
| Stiftung zur Erforschung der Vaskulären Demenz | 22cVd01 |
| Deutsche Forschungsgemeinschaft | 540798028 |
| Ludwig-Maximilians-Universität | 1216/1176 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
DFG Research Classification Scheme
- 2.23-07 Clinical Neurology, Neurosurgery and Neuroradiology
Fingerprint
Dive into the research topics of 'Brain-derived tau for monitoring brain injury in acute ischemic stroke'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver